Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

BACKGROUND: The use of imatinib, an ABL tyrosine kinase inhibitor, has led to a dramatic change in the management of BCR-ABL-positive leukemia patients. However, resistance to imatinib mediated by mutations in the BCR-ABL domain has become a major problem in the treatment of these patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635933/
https://www.ncbi.nlm.nih.gov/pubmed/23556431
http://dx.doi.org/10.1186/1475-2867-13-32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635933/
https://www.ncbi.nlm.nih.gov/pubmed/23556431
http://dx.doi.org/10.1186/1475-2867-13-32

Ejemplares similares